RESEARCH CASE STUDY Role of Exercise in Metabolic Associated Fatty Liver Disease (Filmed 2024)
Dr. Shelley Keating AES AEP* is an Accredited Exercise Physiologist, a researcher, and a senior lecturer at the School of Human Movement and Nutrition Sciences at the University of Queensland in Brisbane, Australia. Dr. Keating’s research primarily focuses on the role of exercise in the management of metabolic dysfunction associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease. MASLD affects a significant portion of the global adult population, with many individuals unaware of their condition.
The condition is strongly linked with the development of Type 2 diabetes, heart disease, and various liver-related consequences. Dr. Keating’s research emphasises lifestyle interventions, particularly the role of exercise, in managing MASLD. Her work has shown that aerobic exercise, independent of weight loss, plays a crucial role in reducing liver fat and improving liver health.
Through clinical trials, Dr. Keating and her team have explored the impact of different doses of supervised aerobic exercise on individuals with obesity and MASLD. Their findings suggest that aerobic exercise, at various durations and intensities, yields benefits for reducing liver fat. They recommend 150 to 240 minutes of moderate to vigorous intensity aerobic exercise per week as beneficial for improving liver health. Moreover, even lower doses of exercise, such as 135 minutes per week, have shown positive effects.
Dr. Keating has collaborated with Exercise and Sports Science Australia and international experts in creating exercise guidelines for the management of MASLD, which have been adopted in numerous policies and guidelines worldwide. Currently, her focus is on designing tailored exercise solutions to help individuals living with MASLD sustain long-term exercise behaviours based on their needs, perspectives, and experiences.
* AES is the acronym for Accredited Exercise Scientist (AES), AEP is the acronym for Accredited Exercise Physiologist
-
Good and bad extracellular vesicles in health and disease
Associate Professor Joy Wolfram has joint appointments in the School of Chemical Engineering and the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland, and through her work at the AIBN, she aims to develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat life-threatening diseases that are major causes of death globally, including cardiovascular disease, kidney disease, and breast cancer.
-
Respiratory health and the microbiome in the lung environment
Dr Taylor leads the Respiratory Health Group within the Microbiome and Host Health Program. His research employs tailored techniques that allow the lung environment to be characterised to a high level of accuracy, including detailed measurements of airway microbiology (microbiome), mucus composition, and inflammation. This information is used to identify predictive markers of chronic lung disease severity as well as determine effective forms of therapy.
-
Touched by bowel cancer and chasing science outcomes
Dr Josephine Wright is a Senior Research Fellow in the Gut Cancer group. She has been developing a translational network of labs, hospitals and clinics to enable validation of new approaches to prevent and treat colorectal and gastric cancer. Her key focus is studying human tumour organoids to better personalise therapy in cancer.
